EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Inhibrx Biosciences's enterprise value is $106.14 Mil.
Inhibrx Biosciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was $0.20 Mil. Therefore, Inhibrx Biosciences's EV-to-Revenue for today is 530.68.
The historical rank and industry rank for Inhibrx Biosciences's EV-to-Revenue or its related term are showing as below:
INBX'
s EV-to-Revenue Range Over the Past 10 Years
Min: -33.04 Med: 124.67 Max: 604.74
Current: 530.68
During the past 3 years, the highest EV-to-Revenue of Inhibrx Biosciences was 604.74. The lowest was -33.04. And the median was 124.67.
INBX's EV-to-Revenue is ranked worse than 93.67% of 995
companies
in the Biotechnology industry
Industry Median: 7.6
vs INBX: 530.68
The historical data trend for Inhibrx Biosciences's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Inhibrx Biosciences's EV-to-Revenue
For the Biotechnology subindustry, Inhibrx Biosciences's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inhibrx Biosciences's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Inhibrx Biosciences's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Inhibrx Biosciences's EV-to-Revenue falls into.
Inhibrx Biosciences's current Enterprise Value is $106.14 Mil.
Inhibrx Biosciences's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.20 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inhibrx Biosciences's share price for today is $14.56.
Inhibrx Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inhibrx Biosciences EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Inhibrx Biosciences's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
INBX has been successfully added to your 